In the previous issue, we released ProteinT's "Health Check Upgrade Trio" (New Product Release | Give health check centres one more "repurchase weapon" — ProteinT's "Health Check Upgrade Trio" is here!). Many health check centres have been asking the same question: if only one upgrade item is to be added first, which one should come first? Our answer is: start with "risk stratification". Because only when risks are seen clearly first can the later management and retesting have direction.

Why should a health check upgrade start with "risk stratification"?

Many customers have health checks year after year, with both CT and ultrasound done, and their reports say "no abnormality found" — yet they still feel uneasy. Why? Because most tests see: changes that have already formed (things that have grown out). But abnormalities in the human body often send signals at the molecular level before morphological changes occur. What ELIXIR-Puente aims to do is capture these signals.

What is ELIXIR-Puente?

A disease risk assessment platform built on whole-molecular blood signals and AI algorithms, obtaining multi-dimensional information from blood through nuclear magnetic resonance spectroscopy. It turns "risks you cannot understand" into "levels you can distinguish". The platform is trained on a model based on more than 100,000 cases, identifying and stratifying complex human health states.

Through a single blood test, it comprehensively assesses the following risks: lung cancer, gastric cancer, liver cancer, and cardiovascular and cerebrovascular diseases.

More importantly, it does not simply judge "whether there is a problem", but directly provides risk stratification + next-step recommendations, for example:

Low risk: maintain the current state and monitor regularly; High risk: recommend further imaging examination and initiate intervention. Let customers know: which stratum I am in now, and what I should do.

Its relationship with existing testing methods: not a replacement, but a complement

Many health check centres worry: will this replace existing items? The answer is clear: no, it is complementary.

You can understand it this way: imaging (CT / ultrasound): see "whether something has grown out"; tumour markers: see "whether a certain indicator is abnormal"; genetic testing: see "whether there is an innate risk". What ELIXIR-Puente does is: before all of these, make the risk level clear first. It fills a key gap: the stage between "no abnormality has formed yet" and "it can already be seen".

Why should health check centres pay attention to it?

This is not just "one more test", but a change in the service entry point.

① Earlier risk alerts: no longer waiting until "something has grown" to discover it, but beginning intervention at an earlier stage.

② Clearer delivery of results: not vague advice, but clear stratification + a definite pathway. Customers truly "understand their health check results" for the first time.

③ Naturally generating follow-up services: once stratification exists, follow-up pathways emerge — some enter further examination, some enter health management, and everyone enters continuous tracking and retesting. A health check goes from "a one-time test" to "continuous service". Every customer now has a reason to be reached again and to be retested.

What does the customer ultimately receive?

Not dozens of pages of complex indicators, but a very clear result: a one-page conclusion: multi-organ risks at a glance; an action list: what specifically to do next; a retesting loop: when to recheck and how to judge whether there has been improvement. From "reading a report" to "being able to act".

Applicable scenarios

It can be directly used as: a high-end health check upgrade item: a deep supplement to existing packages; corporate executive health management: discover risks earlier and reduce sudden health events; membership benefit enhancement: provide high-end members with risk early warning "prior to imaging".

First-phase trial package | 20 cases now open for application

ELIXIR-Puente has been included in the "Health Check Upgrade Trio" trial package:

Content: ELIXIR-Puente + Zhihang™ 14 items + MiMi™ Pro

Trial settlement price: 1,268 RMB per person (combined reference price 6,340 RMB)

Trial scale: 20 cases (fixed combination, not to be split)

How to apply

Reply with [Trio] to book a 15-minute discussion and confirm the cooperation pathway and contact method.

Compliance statement

This product is for health management reference and does not replace clinical diagnosis and treatment. Expressions such as "guarantee / cure / predict compensation / replace doctors" are strictly prohibited. Cooperation must comply with the unified price system: no inversion, no cross-region diversion, and no split sales.

ProteinT empowers health management with technology, so that health checks are not only seen, but can be put to use.

ProteinT / 谱天生物

INNOVATION FOR NEXT GENERATION

ProteinT is a national-level high-tech enterprise focused on the field of precision medicine multi-omics. As the lead unit of the Tianjin Key Laboratory of Clinical Multi-Omics, it took the lead in conducting "gene + protein + metabolism" multi-omics research, and its independently developed proteomics liquid biopsy technology is at an internationally leading level. Core team members come from well-known research institutions at home and abroad, including Yale University, the National Institutes of Health (USA), and the National Center for Protein Sciences. Its R&D pipeline covers common single cancers and pan-cancer types such as liver, lung, gastric, esophageal, colorectal, and pancreatic cancers, and extends to major chronic diseases such as cardiovascular and cerebrovascular diseases, focusing on key research directions including early screening and early diagnosis, recurrence monitoring, and medication guidance. Its Umbrella™ clinical molecular database, with core intellectual property rights, contains more than 100,000 clinical sample records. ProteinT is committed to continuous technological innovation and clinical translation of cutting-edge achievements, advancing precision medicine and exploring the infinite possibilities of human health.